Publications by authors named "P Beaulieu"
Objectives: Our primary objective was to assess the association between symptoms at the time of surgery and postoperative pulmonary complications and mortality in patients with COVID-19. Our secondary objective was to compare postoperative outcomes between patients who had recovered from COVID-19 and asymptomatic patients and explore the effect of the time elapsed between infection and surgery in the former. Our hypotheses were that symptomatic patients had a higher risk of pulmonary complications, whereas patients who had recovered from the infection would exhibit outcomes similar to those of asymptomatic patients.
View Article and Find Full Text PDFEfficacy of cannabinoids compared to the current standard treatments on symptom relief in persons with multiple sclerosis (CANSEP trial): study protocol for a randomized clinical trial.
Front Neurol
July 2024
Article Synopsis
- Multiple sclerosis (MS) is a debilitating disease affecting over 90,000 Canadians, and current treatments only offer limited relief; many patients turn to cannabis for symptom management despite the lack of solid scientific backing.
- This clinical trial seeks to evaluate the effectiveness of various doses of cannabinoids (THC and CBD), both individually and in combination, for alleviating spasticity in MS patients, comparing results against a placebo group.
- The study will involve 250 participants and utilize a double-blind, randomized design, measuring outcomes such as self-reported spasticity, pain, and quality of life over a period of four weeks, with potential for an additional 12-week treatment phase for those who respond well.
ATR is a key kinase in the DNA-damage response (DDR) that is synthetic lethal with several other DDR proteins, making it an attractive target for the treatment of genetically selected solid tumors. Herein we describe the discovery of a novel ATR inhibitor guided by a pharmacophore model to position a key hydrogen bond. Optimization was driven by potency and selectivity over the related kinase mTOR, resulting in the identification of camonsertib (RP-3500) with high potency and excellent ADME properties.
View Article and Find Full Text PDFArticle Synopsis
- Childhood cancer survivors may face a higher risk of neurocognitive deficits, anxiety, and depression, as indicated by various genetic associations identified through whole-exome sequencing of acute lymphoblastic leukemia (ALL) survivors.
- Notable findings include significant links between the AK8 gene and neurocognitive function, as well as associations of anxiety with genes like PTPRZ1 and MUC16, with variations seen depending on sex and risk groups.
- The study highlights the potential of specific genes, particularly ZNF382 and EXO5, in understanding neuropsychological complications among survivors, emphasizing the need for further research to validate these associations.
Background: Alterations of FLT3 are among the most common driver events in acute leukaemia with important clinical implications, since it allows patient classification into prognostic groups and the possibility of personalising therapy thanks to the availability of FLT3 inhibitors. Most of the knowledge on FLT3 implications comes from the study of acute myeloid leukaemia and so far, few studies have been performed in other leukaemias.
Methods: A comprehensive genomic (DNA-seq in 267 patients) and transcriptomic (RNA-seq in 160 patients) analysis of FLT3 in 342 childhood acute lymphoblastic leukaemia (ALL) patients was performed.